Colgate-Palmolive Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Colgate-Palmolive Stock Outlook: Is Wall Street Bullish or Bearish?

Earnings report AI-generated analysis

📈 CL shares have rallied 30.1% over the past year, significantly outperforming the S&P 500 Index and the XLP consumer staples ETF.

🚀 In 2026, the stock has grown by nearly 26.6%, demonstrating strong relative performance against the broader market index.

💰 Q3 2026 revenue rose 4.6% year-over-year to $5.4 billion, successfully surpassing analyst consensus estimates.

📊 Adjusted EPS for the quarter reached $0.97, topping market expectations and indicating healthy profitability.

📈 Sales volumes and organic revenue both grew in Q3 2026, reflecting robust underlying demand for Colgate's product portfolio.

🔮 Analysts project full-year 2026 EPS to rise 6% to $3.91 on a diluted basis, building on four consecutive quarters of beats.

👥 The consensus rating among 22 analysts is 'Moderate Buy', supported by ten 'Strong Buy' ratings and three 'Moderate Buys'.

💵 The mean analyst price target stands at $100.52, which is currently below the prevailing market price.

🎯 The Street-high price target of $112 implies a potential 11.4% upside from current trading levels.

⚖️ Barclays analyst Lauren Lieberman maintains a 'Hold' rating with a specific price target of $95.

Bullish Signals
  • CL shares have surged 30.1% over the past year, significantly outperforming the S&P 500 Index and the XLP consumer staples ETF.
  • The stock has grown by nearly 26.6% in 2026, demonstrating strong relative performance against the broader market index.
  • Q3 2026 revenue rose 4.6% year-over-year to $5.4 billion, successfully surpassing analyst consensus estimates.
  • Adjusted EPS for the quarter reached $0.97, topping market expectations and indicating healthy profitability.
  • Sales volumes and organic revenue both grew in Q3 2026, reflecting robust underlying demand for Colgate's product portfolio.
  • Analysts project full-year 2026 EPS to rise 6% to $3.91 on a diluted basis, building on four consecutive quarters of beats.
  • The consensus rating among 22 analysts is 'Moderate Buy', supported by ten 'Strong Buy' ratings and three 'Moderate Buys'.
  • The Street-high price target of $112 implies a potential 11.4% upside from current trading levels.
Risk Factors
  • Barclays analyst Lauren Lieberman maintains a 'Hold' rating with a specific price target of $95, which is below the current market price.
  • The mean analyst price target of $100.52 is currently below the prevailing market price, suggesting limited immediate upside according to average consensus.
Full Analysis
Colgate-Palmolive Company (CL) has significantly outperformed the broader market and its sector peers over the past year, with shares surging 30.1% compared to the S&P 500's 13.5% gain. This strong momentum continued into 2026, where CL rose nearly 26.6% against the index's 12.3% increase, while also beating the State Street Consumer Staples Select Sector SPDR ETF (XLP) which gained 18.4% during the same period. The company delivered robust financial results in its Q3 2026 earnings report released on October 30, with revenue increasing 4.6% year-over-year to $5.4 billion, surpassing Wall Street estimates. Adjusted earnings per share reached $0.97, also exceeding consensus expectations, driven by growth in both sales volumes and organic revenue that signals sustained consumer demand for its oral, personal, and home care products. Analysts maintain a 'Moderate Buy' consensus rating on CL based on 22 covers, with the average price target set at $100.52, which is currently below the market price. While Barclays analyst Lauren Lieberman maintains a 'Hold' rating with a $95 target, the Street-high target of $112 suggests potential upside, and expectations for full-year 2026 EPS growth of 6% to $3.91 reflect continued confidence in the company's performance.